Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 713-719

  Rosborough, Terry K ^a   Shepherd, Michele F ^a  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

Antifactor Xa activity; Dosage protocol; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; HEPARIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD CLOTTING; BODY HEIGHT; BODY WEIGHT; COMPUTER ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; GENDER; HEPARINIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; TREATMENT INDICATION; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY HEIGHT; BODY WEIGHT; CLINICAL PROTOCOLS; DRUG MONITORING; FACTOR XA; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 2942614745     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.713.36067     Document Type: Article

References (63)

1. Juhan-Vague I, Riera H, Ailaud MF, Verdet D, Sambuc R. Measurement of blood heparin levels: variation in results with assay method [letter]. Thromb Haemost 1982;47:295.
2. Marci CD, Prager D. A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 1993;99:546-50.
3. Hirsh J, Warkenton TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:S64-94.
4. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997;108:662-8.
5. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
6. Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999;19:922-31.
7. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158:1140-3.
8. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
9. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ration to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001;161:385-91.
10. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138: 720-3.
11. Holm HA, Abildgaard U, Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 1985;53:278-81.
12. Scully MF, Decousus HA, Ellis V, Parker C, Girard P, Kakkar VV. Measurement of heparin in plasma: influence of intersubject and circadian variability in heparin sensitivity according to method. Thrombos Res 1987;46:447-55.
13. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
14. Mesters RM, Mikoteit T, Schiller M, Krings W, Ostermann H, Kienast J. Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: a prospective study in acute deep venous thrombosis. Blood Coagul Fibrinolysis 1995;6:665-71.
15. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant effects of heparin in experimental venous thrombosis. Blood 1977;49:171-84.
16. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-5.
17. Elliott CG, Michoki RJ, Brown R, Ottesen OE. Heparin requirements in pulmonary embolism and venous thrombosis: a prospective study. J Clin Pharmacol 1982;22:102-9.
18. Hattersley PG, Mitsuoka JC, Ignoffo RJ, King JH, Musallam NA. Adjusting heparin infusion rates from the initial response to activated coagulation time. Drug Intell Clin Pharm 1983;17:632-4.
19. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874-81.
20. Shalansky KF, FitzGerald JM, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996;16:1076-84.
21. Lackie CL, Luzier AB, Donovan JA, Feras HI, Forrest A. Weight-based heparin dosing: clinical response and resource utilization. Clin Ther 1998;20:699-710.
22. Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemost 1981;45:24-6.
23. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E. Heparin kinetics: variable related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
24. Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med 1981;70:808-16.
25. Groce JB, Gal P, Douglas JB, Steuterman MC. Heparin dosage adjustment in patients with deep vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm 1987;6:216-22.
26. Kershaw B, White RH, Mungall D, Van Houten J, Brettfeld S. Computer-assisted dosing of heparin: management with a pharmacy-based anticoagulation service. Arch Intern Med 1994;154:1005-11.
27. Estes JW, Pelikan EW, Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969;10:329-37.
28. Estes JW, Poulin PF. Pharmacokinetics of heparin: distribution and elimination. Thromb Diath Haemorrh 1974;33:26-37.
29. Perry PM, Herran GR, King JC. Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther 1974;16:514-19.
30. Estes JW. The fate of heparin in the body. Curr Ther Res Clin Exp 1975;18:45-7.
31. Chenella FC, Gill MA, Kern JW, Floyd RA, McGehee WG. Improved method for estimating initial heparin infusion rates. Am J Hosp Pharm 1979;36:782-4.
32. Talstad I. Heparin therapy adjusted for body weight. Am J Clin Pathol 1985;83:378-81.
33. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang BS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956;5:328-45.
34. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-8.
35. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health-Syst Pharm 1998;55:159-62.
36. Rosborough TK. In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone. Pharmacotherapy 1998;18:1217-23.
37. Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacotherapy 1999;19:760-6.
38. de Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-8.
39. Chenella FC, Klotz TA, Gill MA, et al. Blood sampling strategy for monitoring continuous intravenous heparin therapy. Clin Pharm 1986;5:510-13.
40. Mungall D, Lord M, Cason S, Treadwell P, Williams D, Tedrick D. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes. Am J Cardiol 1998;82:574-9.
41. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
42. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
43. Smythe MA, Koerber JM. Heparin monitoring: the confusion continues. Pharmacotherapy 1999;19:1240-2.
44. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8.
45. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.
46. Trujillo TC, Nolan PE. Unfractionated heparin in acute coronary syndromes: has its time come and gone? Am J Health-Syst Pharm 1998;55:2402-9
47. Wright RR, Tone M, Pollycove M. Blood volume. Semin Nucl Med 1975;5:63-78.
48. Campbell RC, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med 1997;156:857-60.
49. White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med 1997;157:2468-72.
50. Lijnen HR, Hoylaerts M, Colleen D. Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983;258:3803-8.
51. Levine SP, Sorenson RR, Harris MA, Knierem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984;57:585-96.
52. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem 1987;262:12247-53.
53. Young E, Prins MH, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-43.
54. Rosborough TK, Shepherd MF. Heparin resistance as detected with an antifactor Xa assay is not more common in venous thromboembolism than in other thromboembolic conditions. Pharmacotherapy 2003;23:142-6.
55. Joch LE, Lutomski DM, Williams DJ, Bottorff M. Accuracy of a first-order model for estimating initial heparin dosage. Clin Pharm 1993;12:597-601.
56. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;29:387-93.
57. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary disease. Am Heart J 1999;137:72-8.
58. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-18.
59. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547-8.
60. Emanuele RM, Racanelli A, Fareed J. Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. Ther Drug Monit 1988;10:153-9.
61. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration on ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-9.
62. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-17.
63. Sephton V, Farquharson RG, Topping J, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003;101:1307-11.